Second generation TKIs increased cell activation (CD69) and decreased expression of NKp44 and NKp80 by NKT-like cells from CML patients when compared to Imatinib. This evidence concerns the gene CD69 and chronic myelogenous leukemia, BCR-ABL1 positive.